Home > Press > INBRAIN Neuroelectronics raises over €14M to develop smart graphene-based neural implants for personalised therapies in brain disorders
![]() |
Abstract:
INBRAIN Neuroelectronics, a spin-off company of the Catalan Institute of Nanoscience and Nanotechnology (ICN2) and ICREA, announces a €14.35M Series A investment, co-led by Asabys Partners and Alta Life Sciences, and joined by Vsquared Ventures (Germany), TruVenturo (Germany) and CDTI (Spanish Ministry of Science and Innovation). INBRAIN has the mission to develop intelligent neuroelectronic therapies based on graphene technology for application in patients with epilepsy, Parkinson’s and other brain related disorders.
In June 2020, INBRAIN received a first seed investment from a syndicate of investors led by Asabys Partners (through Sabadell-Asabys Health Innovation Investment) and Alta Life Sciences, including the Institut Català de Finances (ICF), Finaves (IESE Business School) and BStartUp. Today the company announces a €14.35M Series A investment, one of the biggest rounds in the Spanish medtech industry, co-led by Asabys Partners and Alta Life Sciences, and joined by Vsquared Ventures, a deep tech focused early-stage venture capitalist based in Munich (Germany), TruVenturo GmbH, Germany’s most successful tech and life science company builders, and CDTI (Spanish Ministry of Science and Innovation). The financing round also counts with the follow-on investment from ICF Venture Tech II, investment fund from the ICF.
This investment will allow INBRAIN to bring for the first time this technology, built around an innovative nanoscale graphene electrode, to humans and to consolidate the safety of the material as the potential new standard of care in neurotechnologies.
According to a 2010 study commissioned by the European Brain Council, the cost of brain disorders in Europe alone reaches approximately 800 billion euros a year, with more than one-third of the population affected. Between 25% and 35% of patients having a neuronal disease are refractory to pharmacological treatment and are left without an effective therapy. The high incidence of brain-related diseases worldwide and their huge social cost call for greater investments in basic research in this field, with the aim of developing new and more efficient therapeutic and diagnostic tools.
Existing brain interfaces are based on metals (such as platinum and iridium), with significant restrictions on miniaturization and signal resolution, and therefore responsible for considerable side effects. As a consequence, there is a 50% rejection rate in candidate patients. INBRAIN Neuroelectronics’ disruptive technology, based on the novel material graphene, will overcome the current limitations of metal-based neural interfaces.
INBRAIN Neuroelectronics is bringing a complete technological transformation to the treatment of neurological diseases. Its brain implantable intelligent systems are based on graphene electrodes, which allow miniaturization to nanoscale fabrication, with the potential to reach single-neuron resolution. The extraordinary properties of graphene ̶ which is light, biocompatible, flexible and extremely conductive ̶ are harnessed in much smaller devices that are safer to implant and can be programmed, upgraded and recharged wirelessly.
Driven by artificial intelligence, the implant can learn from the brain of the specific patient and trigger adaptive responses to deliver a personalised neurological therapy. In addition, the use of Big Data Management will permit remote monitoring of the device and data processing. The technology has already been validated in in-vitro and in-vivo, biocompatibility and toxicity tests have been successful. Studies on large animals have been completed and the investment will be dedicated to bring the technology to human patients, in collaboration with key neurosurgical and neurological groups in Europe.
"The success in supporting innovation is multiple," comments Dr Pablo Pomposiello, Head of the ICN2 Business and Innovation Unit. "Most importantly, the capital raised will allow testing in humans of the novel graphene-based technology that one day might alleviate the suffering from neurological disease. But also, the investment validates the vision that public and private sectors can collaborate and accelerate innovation. Finally, it shows that relative small centers like ICN2 can achieve world-class results by sustaining internal, long term investment in promising projects.
INBRAIN is directed by Carolina Aguilar (Former Medtronic Deep Brain Stimulation European and Global Commercialization Director) and was founded, among others, by ICREA Prof. Jose A. Garrido, leader of the ICN2 Advanced Electronic Materials and Devices Group, Prof. Kostas Kostarelos, leader of the ICN2 Nanomedicine Group and Professor and Chair of Nanomedicine at the National Graphene Institute and the Faculty of Biology, Medicine and Health of the University of Manchester (UK), and Dr Anton Guimerà, a researcher at the Barcelona Institute of Microelectronics (IMB-CNM-CSIC). The technology development team is formed by neurotechnology experts such as Bert Bakker (CTO) and Michel Decre (Technology Advisor & Board Member) from Philips and other European successful neurotechnology startups.
####
For more information, please click here
Contacts:
Virginia Greco
Phone: 622369267
Fax: 08193
Comments: Edifici ICN2 - Campus UAB
Av. de Serragalliners s/n
Copyright © ICN2
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
News and information
Inverted perovskite solar cell breaks 25% efficiency record: Researchers improve cell efficiency using a combination of molecules to address different November 17th, 2023
Night-time radiative warming using the atmosphere November 17th, 2023
A new kind of magnetism November 17th, 2023
Graphene/ Graphite
Ferroelectrically modulate the Fermi level of graphene oxide to enhance SERS response November 3rd, 2023
2 Dimensional Materials
Nanoparticle quasicrystal constructed with DNA: The breakthrough opens the way for designing and building more complex structures November 3rd, 2023
What a “2D” quantum superfluid feels like to the touch November 3rd, 2023
Possible Futures
Shedding light on unique conduction mechanisms in a new type of perovskite oxide November 17th, 2023
Silver nanoparticles: guaranteeing antimicrobial safe-tea November 17th, 2023
Three-pronged approach discerns qualities of quantum spin liquids November 17th, 2023
Inverted perovskite solar cell breaks 25% efficiency record: Researchers improve cell efficiency using a combination of molecules to address different November 17th, 2023
Investments/IPO's/Splits
Daikin Industries becomes OCSiAl shareholder July 27th, 2021
180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021
Nanomedicine
Silver nanoparticles: guaranteeing antimicrobial safe-tea November 17th, 2023
Super-efficient laser light-induced detection of cancer cell-derived nanoparticles: Skipping ultracentrifugation, detection time reduced from hours to minutes! October 6th, 2023
The medicine of the future could be artificial life forms October 6th, 2023
Discoveries
Inverted perovskite solar cell breaks 25% efficiency record: Researchers improve cell efficiency using a combination of molecules to address different November 17th, 2023
Night-time radiative warming using the atmosphere November 17th, 2023
A new kind of magnetism November 17th, 2023
Announcements
Inverted perovskite solar cell breaks 25% efficiency record: Researchers improve cell efficiency using a combination of molecules to address different November 17th, 2023
Night-time radiative warming using the atmosphere November 17th, 2023
A new kind of magnetism November 17th, 2023
![]() |
||
![]() |
||
The latest news from around the world, FREE | ||
![]() |
![]() |
||
Premium Products | ||
![]() |
||
Only the news you want to read!
Learn More |
||
![]() |
||
Full-service, expert consulting
Learn More |
||
![]() |